Disease · MONDO_0008661
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause | 0 of 326 | 0 of 115 | 441 | NCT04057573 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events | 6 of 326 | 0 of 115 | 441 | NCT04057573 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause | 0 of 311 | 0 of 109 | 420 | NCT04052425 | Trial comparisons |
| Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events | 8 of 311 | 1 of 109 | 420 | NCT04052425 | Trial comparisons |
| Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 114 of 228 | 39 of 115 | 343 | NCT04057573 | Trial comparisons |
| Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 101 of 221 | 42 of 109 | 330 | NCT04052425 | Trial comparisons |
Treatment-Extension Period: Ruxolitinib Cream 1.5% BID vs Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | 82 of 199 | 38 of 98 | 297 | NCT04057573 | Trial comparisons |
Treatment-Extension Period: Ruxolitinib Cream 1.5% BID vs Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period | 65 of 193 | 31 of 90 | 283 | NCT04052425 | Trial comparisons |
| AMG 714 vs Placebo: deaths from any cause | 0 of 41 | 0 of 18 | 59 | NCT04338581 | Trial comparisons |
| AMG 714 vs Placebo: serious adverse events | 0 of 41 | 0 of 18 | 59 | NCT04338581 | Trial comparisons |
| Ruxolitinib 1.5% Cream BID vs Ruxolitinib 1.5% Cream BID + NB-UVB: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 9 of 20 | 21 of 35 | 55 | NCT05247489 | Trial comparisons |
| Intervention Arm vs Placebo Arm: serious adverse events | 1 of 8 | 0 of 7 | 15 | NCT01517893 | Trial comparisons |
| Intervention Arm vs Placebo Arm: Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score | 0 of 5 | 0 of 7 | 12 | NCT01517893 | Trial comparisons |
| Intervention Arm vs Placebo Arm: Number of Participants Experiencing Toxicity From of High-dose Simvastatin . | 0 of 5 | 0 of 7 | 12 | NCT01517893 | Trial comparisons |
| Intervention Arm vs Placebo Arm: Number of Participants With Increase in Investigator's Global Assessment Score | 1 of 5 | 0 of 6 | 11 | NCT01517893 | Trial comparisons |
| Intervention Arm vs Placebo Arm: Number of Participants With an Increase in Patient's Global Assessment Score | 0 of 5 | 1 of 6 | 11 | NCT01517893 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008661/comparisons